CN104010650A - 长效生长激素及其生产方法 - Google Patents

长效生长激素及其生产方法 Download PDF

Info

Publication number
CN104010650A
CN104010650A CN201280048492.0A CN201280048492A CN104010650A CN 104010650 A CN104010650 A CN 104010650A CN 201280048492 A CN201280048492 A CN 201280048492A CN 104010650 A CN104010650 A CN 104010650A
Authority
CN
China
Prior art keywords
ctp
growth hormone
another embodiment
hgh
methods according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280048492.0A
Other languages
English (en)
Chinese (zh)
Inventor
福阿德·法里斯
乌迪·埃亚尔·菲玛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opko Biologics Ltd
Original Assignee
Opko Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Biologics Ltd filed Critical Opko Biologics Ltd
Priority to CN201710103795.2A priority Critical patent/CN107080835A/zh
Publication of CN104010650A publication Critical patent/CN104010650A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280048492.0A 2011-08-02 2012-08-02 长效生长激素及其生产方法 Pending CN104010650A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710103795.2A CN107080835A (zh) 2011-08-02 2012-08-02 长效生长激素及其生产方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/195,931 US8450269B2 (en) 2006-02-03 2011-08-02 Long-acting growth hormone and methods of producing same
US13/195,931 2011-08-02
PCT/IL2012/050288 WO2013018098A2 (en) 2011-08-02 2012-08-02 Long-acting growth hormone and methods of producing same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710103795.2A Division CN107080835A (zh) 2011-08-02 2012-08-02 长效生长激素及其生产方法

Publications (1)

Publication Number Publication Date
CN104010650A true CN104010650A (zh) 2014-08-27

Family

ID=47629749

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280048492.0A Pending CN104010650A (zh) 2011-08-02 2012-08-02 长效生长激素及其生产方法
CN201710103795.2A Pending CN107080835A (zh) 2011-08-02 2012-08-02 长效生长激素及其生产方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710103795.2A Pending CN107080835A (zh) 2011-08-02 2012-08-02 长效生长激素及其生产方法

Country Status (23)

Country Link
US (1) US8450269B2 (cg-RX-API-DMAC7.html)
EP (2) EP3482765B1 (cg-RX-API-DMAC7.html)
JP (1) JP6153930B2 (cg-RX-API-DMAC7.html)
KR (3) KR102028524B1 (cg-RX-API-DMAC7.html)
CN (2) CN104010650A (cg-RX-API-DMAC7.html)
AU (1) AU2012291617B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014002491A2 (cg-RX-API-DMAC7.html)
CA (1) CA2843672A1 (cg-RX-API-DMAC7.html)
CL (2) CL2014000254A1 (cg-RX-API-DMAC7.html)
CO (1) CO7020850A2 (cg-RX-API-DMAC7.html)
DK (2) DK3482765T5 (cg-RX-API-DMAC7.html)
EA (2) EA035352B1 (cg-RX-API-DMAC7.html)
ES (2) ES2983610T3 (cg-RX-API-DMAC7.html)
FI (1) FI3482765T3 (cg-RX-API-DMAC7.html)
HK (1) HK1200349A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20240635T1 (cg-RX-API-DMAC7.html)
HU (2) HUE066552T2 (cg-RX-API-DMAC7.html)
MX (2) MX360802B (cg-RX-API-DMAC7.html)
PL (2) PL3482765T3 (cg-RX-API-DMAC7.html)
PT (2) PT2739298T (cg-RX-API-DMAC7.html)
SI (2) SI2739298T1 (cg-RX-API-DMAC7.html)
TR (1) TR201821186T4 (cg-RX-API-DMAC7.html)
WO (1) WO2013018098A2 (cg-RX-API-DMAC7.html)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107438623A (zh) * 2014-12-10 2017-12-05 Opko生物科学有限公司 长效的ctp修饰的生长激素多肽的制备方法
CN108289851A (zh) * 2015-06-19 2018-07-17 Opko生物科学有限公司 长效凝固因子及其产生方法
CN108676096A (zh) * 2018-05-22 2018-10-19 北京伟杰信生物科技有限公司 重组猪fsh-ctp融合蛋白及其制备方法与应用
CN112175964A (zh) * 2020-10-23 2021-01-05 安徽中起生物科技有限公司 一种重组猪生长激素及其制备方法和应用
CN115991792A (zh) * 2022-12-19 2023-04-21 北京伟杰信生物科技有限公司 长效重组lh融合蛋白及其制备方法与应用
US11976106B2 (en) 2016-07-11 2024-05-07 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US7553941B2 (en) 2006-02-03 2009-06-30 Modigene Inc Long-acting polypeptides and methods of producing same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
CA3004716C (en) 2008-04-29 2022-04-12 Ascendis Pharma Endocrinology Division A/S Pegylated recombinant human growth hormone compounds
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
EP2512450B1 (en) 2009-12-15 2018-02-07 Ascendis Pharma Endocrinology Division A/S Dry growth hormone composition transiently linked to a polymer carrier
WO2013157002A1 (en) 2012-04-19 2013-10-24 Prolor Biotech Inc. Long-acting oxyntomodulin variants and methods of producing same
SG11201503879QA (en) * 2012-11-20 2015-06-29 Opko Biolog Ltd Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
CN103524626B (zh) * 2013-09-27 2016-09-07 武汉龙科生物技术有限公司 重组双靶点蛋白药物及其应用
HUE050002T2 (hu) * 2013-10-21 2020-11-30 Opko Biologics Ltd Hosszan ható polipeptidek és eljárás azok elõállítására és beadására
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
KR102608645B1 (ko) 2014-11-18 2023-12-01 아센디스 파마 엔도크리놀로지 디비전 에이/에스 신규한 중합체성 hGH 프로드러그
EP4732848A3 (en) 2014-11-21 2026-07-29 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms
MY184625A (en) * 2014-12-10 2021-04-09 Opko Biologics Ltd Methods of producing long acting ctp-modified growth hormone polypeptides
AU2017205693B2 (en) 2016-01-08 2022-03-31 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low initial NPR-B activity
CA3008015A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release c-type natriuretic peptide agonists with increased neutral endopeptidase stability
JP6968802B2 (ja) 2016-01-08 2021-11-17 アセンディス ファーマ グロース ディスオーダーズ エー／エス 環部分にキャリア結合を有するｃｎｐプロドラッグ
US10835578B2 (en) 2016-01-08 2020-11-17 Ascendis Pharma Growth Disorders A/S CNP prodrugs with large carrier moieties
KR102518217B1 (ko) 2016-01-08 2023-04-04 아센디스 파마 그로우쓰 디스오더스 에이/에스 낮은 npr-c 결합을 갖는 제어 방출성 cnp 작용제
EP4710947A3 (en) 2016-01-08 2026-06-17 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
SI3423103T1 (sl) 2016-03-01 2024-12-31 Ascendis Pharma Bone Diseases A/S Predzdravila PTH
AU2017295938C1 (en) 2016-07-13 2021-10-07 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
KR102611820B1 (ko) 2016-09-29 2023-12-07 아센디스 파마 본 디지즈 에이/에스 낮은 피크 대 트로프 비를 가진 pth 화합물
HUE063235T2 (hu) 2016-09-29 2024-01-28 Ascendis Pharma Bone Diseases As Adagolási rendszer szabályozott leadású PTH vegyülethez
JP7039574B2 (ja) 2016-09-29 2022-03-22 アセンディス ファーマ ボーン ディジージズ エー／エス 放出制御ｐｔｈ化合物の漸増用量設定
RU2768747C2 (ru) 2016-09-29 2022-03-24 Асцендис Фарма Гроус Дизордерс А/С Комбинаторная терапия с агонистами cnp контролируемого высвобождения
CA3093083A1 (en) 2018-03-28 2019-10-03 Ascendis Pharma A/S Conjugates
US12565525B2 (en) 2018-03-28 2026-03-03 Ascendis Pharma Oncology Division A/S IL-2 conjugates
CA3099620A1 (en) 2018-05-18 2019-11-21 Ascendis Pharma Bone Diseases A/S Starting dose of pth conjugates
EP3848388B1 (en) 2018-09-05 2025-08-20 LG Chem, Ltd. Fusion polypeptide comprising polypeptide region that can be o-glycosylated
EP3870694A4 (en) * 2018-10-26 2022-08-17 Tami Bar COMPOSITIONS AND METHODS FOR BIODEGRADING ALCOHOL
AU2020221491B2 (en) 2019-02-11 2025-02-27 Ascendis Pharma Bone Diseases A/S Liquid pharmaceutical formulations of PTH conjugates
EP3923906A1 (en) 2019-02-11 2021-12-22 Ascendis Pharma Growth Disorders A/S Dry pharmaceutical formulations of cnp conjugates
JP7524206B2 (ja) * 2019-03-04 2024-07-29 アセンディス ファーマ エンドクライノロジー ディヴィジョン エー／エス １日ごとのソマトロピンよりも優れた効力を有する長時間作用性成長ホルモン剤形
WO2020254602A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma A/S Conjugates of an electron-donating nitrogen or tertiary amine comprising compounds
AU2020296297B2 (en) 2019-06-21 2025-06-12 Ascendis Pharma A/S Conjugates of heteroaromatic nitrogen-comprising compounds
EP3986477A1 (en) 2019-06-21 2022-04-27 Ascendis Pharma A/S CONJUGATES OF pi-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS
CA3161098A1 (en) 2020-01-03 2021-07-08 Ascendis Pharma A/S Conjugates undergoing intramolecular rearrangements
JP2023510790A (ja) 2020-01-13 2023-03-15 アセンディス ファーマ ボーン ディジージズ エー／エス 副甲状腺機能低下症の治療
CA3178074A1 (en) 2020-06-03 2021-12-09 Nina Gunnarsson Il-2 sequences and uses thereof
CA3184998A1 (en) 2020-08-05 2022-02-10 Samuel WEISBROD Conjugates comprising reversible linkers and uses thereof
AU2021335032A1 (en) 2020-08-28 2023-03-09 Ascendis Pharma Oncology Division A/S Glycosylated IL-2 proteins and uses thereof
IL301411A (en) 2020-09-28 2023-05-01 Ascendis Pharma Bone Diseases As Improvement of physical and mental well-being of patients with hypoparathyroidism
EP4314035A1 (en) 2021-04-01 2024-02-07 Ascendis Pharma A/S Use of long-acting growth hormone for treating inflammation-induced diseases
CN114010765A (zh) * 2021-08-30 2022-02-08 上海延立药业有限公司 一种长效人生长激素
AU2022350937A1 (en) 2021-09-22 2024-03-21 Ascendis Pharma Bone Diseases A/S Long-acting pth compound treatments
AU2022413318A1 (en) 2021-12-13 2024-05-16 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
AU2023276829A1 (en) 2022-05-23 2024-10-31 Ascendis Pharma Growth Disorders A/S Liquid pharmaceutical formulations of cnp compounds
JP2025537527A (ja) 2022-11-02 2025-11-18 アセンディス ファーマ ボーン ディジージズ エー／エス ２つのｐｔｈ化合物を含むｐｔｈ治療レジメン
KR20250162619A (ko) 2023-03-20 2025-11-18 아센디스 파마 그로우쓰 디스오더스 에이/에스 연골무형성증을 가진 인간 대상에서의 흉요추 변형의 치료 방법
EP4773987A1 (en) 2023-09-04 2026-07-15 Ascendis Pharma Bone Diseases A/S Pth treatment of chronic kidney disease
WO2026120176A1 (en) 2024-12-06 2026-06-11 Ascendis Pharma A/S Conjugates comprising an aromatic carbamate-derived reversible linker
WO2026120177A1 (en) 2024-12-06 2026-06-11 Ascendis Pharma A/S Novel long-acting degrader conjugates
WO2026139471A1 (en) 2024-12-23 2026-07-02 Ascendis Pharma Growth Disorders A/S Use of cnp or cnp conjugates such as navepegritide to treat leg curvature in patients with skeletal dysplasia
WO2026150105A1 (en) 2025-01-13 2026-07-16 Ascendis Pharma A/S Fgf23 degrader conjugates

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597797A (en) * 1990-06-07 1997-01-28 Genentech, Inc. Method for treatment or prevention of obesity
CN1191139A (zh) * 1997-01-15 1998-08-26 阿克佐诺贝尔公司 含有促性腺素的液体制剂
CN1528787A (zh) * 2003-10-17 2004-09-15 华东师范大学 生物修饰重组人生长激素复合物及其制备方法
US20100008161A1 (en) * 2007-01-03 2010-01-14 Jae-Hyuk Im Semiconductor memory device

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
JPS5781447A (en) 1980-11-11 1982-05-21 Toyo Jozo Co Ltd Human chorionic gonadotropic hormone c-terminal fragment
US4853332A (en) 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
DE3421468A1 (de) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
DE3751873T2 (de) 1986-04-09 1997-02-13 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
EP0374257B1 (en) 1988-05-06 1994-08-31 Toray Industries, Inc. STABLE INTERFERON $g(b) COMPOSITION
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5705478A (en) 1989-02-21 1998-01-06 Washington University Covalently linked β subunits of the glycoprotein hormones as antagonists
US5792460A (en) 1989-02-21 1998-08-11 Washington University Modified glycoprotein hormones having a CTP at the amino terminus
US5338835A (en) 1989-02-21 1994-08-16 Washington University CTP-extended form of FSH
DE122010000006I2 (de) 1989-02-21 2012-06-21 Univ Washington Modifizierte formen von fortpflanzungshormonen.
US6225449B1 (en) 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US7217689B1 (en) 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
US6028177A (en) 1991-10-04 2000-02-22 Washington University Methods of detecting single-chain forms of the glycoprotein hormone quartet
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
CA2160800C (en) 1993-04-20 2010-06-01 Irving Boime Ctp modified gonadotropic proteins
US6737515B2 (en) 1993-11-19 2004-05-18 Washington University Follicle stimulating hormone-glycosylation analogs
US6238890B1 (en) 1994-02-18 2001-05-29 Washington University Single chain forms of the glycoprotein hormone quartet
US5935924A (en) 1994-04-15 1999-08-10 Genentech, Inc. Treatment of congestive heart failure
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
BR9506313A (pt) 1994-08-12 1997-08-05 Univ Washington Formas de cadeia simples do quarteto de hormônio de glicoproteína
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
US6310183B1 (en) 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
US6103501A (en) 1997-11-17 2000-08-15 Washington University Single chain glycoprotein hormones comprising two β and one α subunits and recombinant production thereof
AU766190B2 (en) 1998-10-16 2003-10-09 Biogen Idec Ma Inc. Interferon-beta fusion proteins and uses
US6514729B1 (en) 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
PE20010288A1 (es) 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
US20020127652A1 (en) 2000-02-11 2002-09-12 Schambye Hans Thalsgard Follicle stimulating hormones
US7094566B2 (en) 2000-03-16 2006-08-22 Amgen Inc., IL-17 receptor like molecules and uses thereof
WO2002043709A1 (fr) 2000-12-01 2002-06-06 Takeda Chemical Industries, Ltd. Procede de production d'une preparation contenant une substance bioactive
JP4409135B2 (ja) 2000-12-01 2010-02-03 武田薬品工業株式会社 生理活性物質含有製剤の製造法
SI1724284T1 (sl) 2000-12-07 2009-12-31 Lilly Co Eli Glp-1 fuzijski proteini
EP1342730B1 (en) 2000-12-11 2006-03-15 Cheil Jedang Corporation Fusion protein having the enhanced in vivo activity of erythropoietin
KR101229995B1 (ko) 2000-12-11 2013-02-06 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
JP5160005B2 (ja) 2000-12-28 2013-03-13 武田薬品工業株式会社 徐放性製剤
EP1356809A4 (en) 2000-12-28 2008-05-14 Takeda Pharmaceutical Sustained release preparations
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
US6824769B2 (en) 2001-08-28 2004-11-30 Vertex Pharmaceuticals Incorporated Optimal compositions and methods thereof for treating HCV infections
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
US7173113B2 (en) 2002-01-31 2007-02-06 The Trustees Of Columbia University In The City Of New York Long-acting hormone and growth factor compositions and uses thereof
US7081446B2 (en) 2002-01-31 2006-07-25 The Trustees Of Columbia University In The City Of New York Long-acting follicle stimulating hormone analogues and uses thereof
US7459435B2 (en) 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7459436B2 (en) 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
EP1595549A4 (en) 2003-02-19 2010-09-22 Takeda Pharmaceutical DISPERSE FOR PREPARATIONS WITH DELAYED RELEASE
JP4683319B2 (ja) 2003-02-19 2011-05-18 武田薬品工業株式会社 徐放性製剤用の分散剤
US7649084B2 (en) 2003-11-12 2010-01-19 University Of Georgia Research Foundation, Inc. Recombinant glycoproteins related to feline thyrotropin
PL1696947T3 (pl) 2003-12-19 2014-08-29 Hoffmann La Roche Zastosowanie erytropoetyny w leczeniu zaburzeń dystrybucji żelaza w przewlekłych chorobach zapalnych jelit
WO2005094873A1 (en) 2004-03-19 2005-10-13 Baxter International Inc. Factor ixa for the treatment of bleeding disorders
RU2396347C2 (ru) 2004-08-17 2010-08-10 Ксл Бехринг Гмбх Модифицированные витамин к-зависимые полипептиды
US8420602B2 (en) * 2004-09-14 2013-04-16 Landon C. G. Miller Endocannabinoid conjugate and a pharmaceutical composition for treatment of neuronal disorders
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
US8476234B2 (en) 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US7553941B2 (en) 2006-02-03 2009-06-30 Modigene Inc Long-acting polypeptides and methods of producing same
US8304386B2 (en) 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
WO2009114959A1 (zh) * 2008-03-20 2009-09-24 中国人民解放军军事医学科学院毒物药物研究所 可注射用缓释药物制剂及其制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597797A (en) * 1990-06-07 1997-01-28 Genentech, Inc. Method for treatment or prevention of obesity
CN1191139A (zh) * 1997-01-15 1998-08-26 阿克佐诺贝尔公司 含有促性腺素的液体制剂
CN1528787A (zh) * 2003-10-17 2004-09-15 华东师范大学 生物修饰重组人生长激素复合物及其制备方法
US20100008161A1 (en) * 2007-01-03 2010-01-14 Jae-Hyuk Im Semiconductor memory device

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107438623A (zh) * 2014-12-10 2017-12-05 Opko生物科学有限公司 长效的ctp修饰的生长激素多肽的制备方法
US12459982B2 (en) 2014-12-10 2025-11-04 Opko Biologistics Ltd. Methods of producing long acting CTP-modified growth hormone polypeptides
CN108289851A (zh) * 2015-06-19 2018-07-17 Opko生物科学有限公司 长效凝固因子及其产生方法
CN108289851B (zh) * 2015-06-19 2021-06-01 Opko生物科学有限公司 长效凝固因子及其产生方法
US11976106B2 (en) 2016-07-11 2024-05-07 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
CN108676096A (zh) * 2018-05-22 2018-10-19 北京伟杰信生物科技有限公司 重组猪fsh-ctp融合蛋白及其制备方法与应用
CN108676096B (zh) * 2018-05-22 2022-03-29 北京伟杰信生物科技有限公司 重组猪fsh-ctp融合蛋白及其制备方法与应用
CN112175964A (zh) * 2020-10-23 2021-01-05 安徽中起生物科技有限公司 一种重组猪生长激素及其制备方法和应用
CN112175964B (zh) * 2020-10-23 2022-03-29 安徽中起生物科技有限公司 一种重组猪生长激素及其制备方法和应用
CN115991792A (zh) * 2022-12-19 2023-04-21 北京伟杰信生物科技有限公司 长效重组lh融合蛋白及其制备方法与应用

Also Published As

Publication number Publication date
AU2012291617B2 (en) 2017-07-06
EP2739298A4 (en) 2015-03-25
MX2014001335A (es) 2016-09-26
EP3482765B1 (en) 2024-02-28
PT2739298T (pt) 2019-01-11
BR112014002491A2 (pt) 2017-02-21
PL2739298T3 (pl) 2019-05-31
EA201490393A1 (ru) 2015-01-30
WO2013018098A2 (en) 2013-02-07
KR20190116526A (ko) 2019-10-14
SI3482765T1 (sl) 2024-06-28
JP6153930B2 (ja) 2017-06-28
ES2983610T3 (es) 2024-10-23
CA2843672A1 (en) 2013-02-07
CO7020850A2 (es) 2014-08-11
CN107080835A (zh) 2017-08-22
ES2706734T3 (es) 2019-04-01
MX360802B (es) 2018-11-16
EA202090577A3 (ru) 2021-06-30
WO2013018098A3 (en) 2013-05-10
US8450269B2 (en) 2013-05-28
EP2739298A2 (en) 2014-06-11
HK1200349A1 (en) 2015-08-07
MX2018014072A (es) 2021-11-16
KR102028524B1 (ko) 2019-10-04
EP2739298B1 (en) 2018-10-03
CL2014000254A1 (es) 2015-01-16
PL3482765T3 (pl) 2024-08-26
KR20210013300A (ko) 2021-02-03
KR20140083973A (ko) 2014-07-04
DK3482765T5 (da) 2024-09-02
PL2739298T4 (pl) 2019-05-31
EA035352B1 (ru) 2020-06-01
EP3482765A1 (en) 2019-05-15
PT3482765T (pt) 2024-05-23
DK2739298T3 (en) 2019-01-28
HUE042755T2 (hu) 2019-07-29
EA202090577A2 (ru) 2021-03-31
FI3482765T3 (fi) 2024-05-16
HRP20240635T1 (hr) 2024-08-02
TR201821186T4 (tr) 2019-01-21
HUE066552T2 (hu) 2024-08-28
US20120035101A1 (en) 2012-02-09
DK3482765T3 (da) 2024-05-21
SI2739298T1 (sl) 2019-03-29
JP2014521684A (ja) 2014-08-28
CL2020002010A1 (es) 2020-12-18
AU2012291617A1 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
US12029780B2 (en) Long-acting polypeptides and methods of producing and administering same
AU2012291617B2 (en) Long-acting growth hormone and methods of producing same
US8304386B2 (en) Long-acting growth hormone and methods of producing same
US10351615B2 (en) Methods of treatment with long-acting growth hormone
JP7445695B2 (ja) 長期活性型ポリペプチドならびに当該ポリペプチドの製造方法および投与方法
US20200131242A1 (en) Methods of treatment with long-acting hormone
HK40008897A (en) Long-acting growth hormone and methods of producing same
HK40008897B (en) Long-acting growth hormone and methods of producing same
HK40034109A (en) Long-acting polypeptides and methods of producing and administering same
US20150126444A1 (en) Long-acting polypeptides and methods of producing and administering same
EA045766B1 (ru) Соматотропный гормон пролонгированного действия и способы его получения
HK1230924A1 (en) Long-acting polypeptides and methods of producing and administering same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1200349

Country of ref document: HK

CB02 Change of applicant information

Address after: Israel Kyle Pieter Gate

Applicant after: OPKO Biology Science Co., Ltd

Address before: Israel: Ciaona

Applicant before: OPKO Biology Science Co., Ltd

COR Change of bibliographic data
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140827

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1200349

Country of ref document: HK